Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
Mariani
Stefania
S
Tornaghi
Lucia
L
Sassone
Marianna
M
Basciani
Sabrina
S
Buzzetti
Raffaella
R
Gambacorti-Passerini
Carlo
C
Spera
Giovanni
G
Gnessi
Lucio
L
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001786:Blood Glucose / Q000032:analysis*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate